

# Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M926CC50B341EN.html>

Date: December 2022

Pages: 69

Price: US\$ 2,000.00 (Single User License)

ID: M926CC50B341EN

## Abstracts

Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Drugs In Development, 2022, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilus influenza is the third, and

causes meningitis in infants. Approximately 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal rigidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If none of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely. Other clinical features include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby's head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

## REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 2, 4 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Meningitis - Overview

Meningitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Meningitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meningitis - Companies Involved in Therapeutics Development

CanSino Biologics Inc

Chengdu Olymvax Biopharmaceuticals Inc

Chongqing Zhifei Biological Products Co Ltd

Jiangsu Kunli Biopharmaceutical Co Ltd

LG Chem Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Linnaeus Bioscience Inc

Matinas BioPharma Holdings Inc

Mycovia Pharmaceuticals Inc

Pfizer Inc

Serum Institute of India Pvt Ltd

TGV Therapeutics

Yisheng Biopharma Co Ltd

Meningitis - Drug Profiles

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile

Product Description

Mechanism Of Action

(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile

Product Description

Mechanism Of Action

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

APX-2039 - Drug Profile

Product Description

Mechanism Of Action

CSB-015 - Drug Profile

Product Description

Mechanism Of Action

flucytosine - Drug Profile

Product Description

Mechanism Of Action

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

LBVD - Drug Profile

Product Description

Mechanism Of Action

meningitis vaccine - Drug Profile

Product Description

Mechanism Of Action

meningitis vaccine - Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A and C] vaccine - Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A, C] vaccine - Drug Profile

Product Description

Mechanism Of Action

meningococcal [serotypes A] vaccine - Drug Profile

Product Description

Mechanism Of Action

MYC-053 - Drug Profile

Product Description

Mechanism Of Action

pneumococcal (13-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

pneumococcal [serotype 4, 6A] vaccine - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Cryptococcal Meningitis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile

Product Description

Mechanism Of Action

VT-1598 - Drug Profile

Product Description

Mechanism Of Action

Meningitis - Dormant Projects

Meningitis - Discontinued Products

Meningitis - Product Development Milestones

Featured News & Press Releases

Oct 23, 2022: Matinas BioPharma to present new MAT2203 (oral amphotericin B) data during IDWeek 2022

Oct 21, 2022: Matinas BioPharma announces positive interim data from the phase 2 EnACT trial of MAT2203 for the treatment of cryptococcal meningitis, exceeding primary endpoint threshold; patient survival in all-oral cohort 4 regimen currently 90%

Oct 19, 2022: Matinas BioPharma announces Infectious Diseases Society of America (IDSA) has selected the EnACT phase 2 trial abstract of MAT2203 as its outstanding abstract and IDSA awardee for IDWeek 2022

Dec 16, 2021: Matinas BioPharma announces unanimous DSMB approval to progress into fourth and final cohort of patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Sep 13, 2021: Matinas BioPharma announces positive data in the ongoing EnACT trial of MAT2203 (Oral Amphotericin B) for the treatment of cryptococcal meningitis, exceeding the prespecified primary endpoint threshold

Aug 16, 2021: Matinas BioPharma announces issuance of U.S. patent protecting

MAT2203 to treat or prevent cryptococcus infections

Oct 19, 2020: Matinas BioPharma announces unanimous DSMB approval to progress into second cohort of patients in the EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Aug 20, 2020: Matinas BioPharma announces publication of results from phase 1 portion of the EnACT study investigating safety and tolerability of MAT2203

Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis

Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis

Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis

Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational

May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio

May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Meningitis, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Meningitis - Pipeline by CanSino Biologics Inc, 2022  
Meningitis - Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022  
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022  
Meningitis - Pipeline by Jiangsu Kunli Biopharmaceutical Co Ltd, 2022  
Meningitis - Pipeline by LG Chem Ltd, 2022  
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022  
Meningitis - Pipeline by Linnaeus Bioscience Inc, 2022  
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, 2022  
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, 2022  
Meningitis - Pipeline by Pfizer Inc, 2022  
Meningitis - Pipeline by Serum Institute of India Pvt Ltd, 2022  
Meningitis - Pipeline by TGV Therapeutics, 2022  
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, 2022  
Meningitis - Dormant Projects, 2022  
Meningitis - Dormant Projects, 2022 (Contd..1)  
Meningitis - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Meningitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M926CC50B341EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M926CC50B341EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

